Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MYGN
MYGN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MYGN News
Myriad Genetics Releases New Data on Prolaris Test
6d ago
Newsfilter
Myriad Genetics Shares Surge 8.3% Amid Optimism for Precise MRD
Jun 29 2026
NASDAQ.COM
Illumina Appoints New Board Member
Jun 24 2026
NASDAQ.COM
Myriad Genetics Expands Precise MRD Test Availability for Cancer Patients
Jun 23 2026
Newsfilter
Myriad Genetics Appoints New Chief Technology Officer
Jun 02 2026
Newsfilter
Myriad Genetics Unveils New Data on MRD Testing Across Cancer Types
May 27 2026
Newsfilter
Myriad Genetics Launches Prolaris + AI Test for Prostate Cancer Prognosis
May 27 2026
NASDAQ.COM
Identifying Potentially Profitable Stocks
May 23 2026
Yahoo Finance
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing
May 15 2026
Newsfilter
Myriad Genetics Reports Q1 2026 Earnings Miss
May 06 2026
seekingalpha
Myriad Genetics Q1 2026 Earnings Call Insights
May 06 2026
seekingalpha
Myriad Genetics Q1 Results: Revenue Growth Amid Wider Losses
May 05 2026
NASDAQ.COM
Myriad Genetics Q1 Earnings Miss Expectations
May 05 2026
seekingalpha
Myriad Genetics to Announce Q1 Earnings on May 5th
May 04 2026
seekingalpha
GeneSight Test Enhances Personalized Mental Health Treatment Insights
Apr 30 2026
Newsfilter
Myriad Genetics to Present New Research at AACR Annual Meeting
Apr 16 2026
Newsfilter
Show More News
